Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	23.63	17.11	38.99	18.27	17.79
Short-Term Investments	20.93	5.07	0	20.28	0
Cash & Cash Equivalents	44.56	22.18	38.99	38.55	17.79
Cash Growth	100.90%	-43.11%	1.14%	116.64%	-52.94%
Receivables	5.27	4.59	3.44	2	4.7
Inventory	19.05	16.8	17.95	13.08	8.16
Other Current Assets	1.06	1.31	1.29	2.1	1.83
Total Current Assets	69.93	44.88	61.67	55.72	32.48
Property, Plant & Equipment	10.88	9.64	9.92	10.41	10.95
Other Long-Term Assets	3.62	1.27	2.08	1.8	1.96
Total Long-Term Assets	14.5	10.91	12	12.21	12.91
Total Assets	84.43	55.79	73.67	67.93	45.39
Accounts Payable	23.87	18.13	23.42	21.15	18.4
Current Debt	21.66	1.12	1.21	59.93	5.44
Other Current Liabilities	0	13.18	8.55	5.39	16.34
Total Current Liabilities	45.53	32.43	33.18	86.47	40.18
Long-Term Debt	4.62	32.36	32.26	4.47	55.49
Other Long-Term Liabilities	0.71	1.64	14.26	4.03	20.05
Total Long-Term Liabilities	5.34	34	46.53	8.5	75.54
Total Liabilities	50.87	66.43	79.7	94.97	115.71
Total Debt	26.28	33.47	33.47	64.4	60.93
Debt Growth	-21.49%	0.01%	-48.03%	5.70%	27.02%
Retained Earnings	-381.55	-389.86	-374.93	-347.35	-340.83
Shareholders' Equity	33.57	-10.64	-6.04	-27.04	-70.32
Net Cash / Debt	18.28	-11.29	5.52	-25.86	-43.13
Net Cash Per Share	0.22	-0.23	0.12	-0.89	-2.91
Working Capital	24.4	12.45	28.49	-30.75	-7.7
Book Value Per Share	0.50	-0.22	-0.14	-0.93	-4.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).